Last reviewed · How we verify

Dexamethasone pellet

Johns Hopkins University · FDA-approved active Small molecule

Dexamethasone is a synthetic glucocorticoid that suppresses the immune system and reduces inflammation by binding to glucocorticoid receptors.

Dexamethasone is a synthetic glucocorticoid that suppresses the immune system and reduces inflammation by binding to glucocorticoid receptors. Used for Inflammatory and immune-mediated conditions requiring localized or sustained corticosteroid delivery.

At a glance

Generic nameDexamethasone pellet
Also known asOzurdex pellet
SponsorJohns Hopkins University
Drug classGlucocorticoid
TargetGlucocorticoid receptor
ModalitySmall molecule
Therapeutic areaImmunology, Inflammation
PhaseFDA-approved

Mechanism of action

Dexamethasone acts as a potent corticosteroid that inhibits phospholipase A2, reducing prostaglandin and leukotriene production, and suppresses T-cell and B-cell proliferation. The pellet formulation provides sustained or localized delivery of the active ingredient. It is commonly used to reduce inflammation and immune-mediated responses in various conditions.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: